Androgenetic Alopecia as an Early Marker of Benign Prostatic Hyperplasia

August 2011 in “ Journal of The American Academy of Dermatology ”

Salvador Arias-Santiago, Miguel Angel Arrabal-Polo, Agustín Buendía-Eisman, Miguel Arrabal-Martin, María Teresa Gutiérrez-Salmerón, María Sierra Girón-Prieto, Antonio Jiménez-Pacheco, Jaime Eduardo Calonje, Ramón Naranjo-Sintes, Armando Zuluaga-Gomez, Salvio Serrano Ortega

androgenetic alopecia benign prostatic hyperplasia AGA prostate volume urinary flow International Prostate Symptom Score IPSS BPH

TLDR Early hair loss may indicate prostate issues.

This study found that early-onset androgenetic alopecia (AGA) may be an early marker of urinary/prostatic symptomatology. Patients with AGA had a larger prostate, lower urinary flow value, and higher International Prostate Symptom Score (IPSS) in comparison with individuals without AGA. AGA was found to be an independent risk factor for a prostate volume greater than 30 mL, urinary flow less than 15 mL/s, and benign prostatic hyperplasia (BPH). The study suggests that dermatologists and primary care physicians should monitor patients with early-onset AGA for the development of urinary symptoms to permit an earlier diagnosis.

View this study on jaad.org →

Discuss this study in the Community →

Research cited in this study

19 / 19 results

research Sex Hormone–Binding Globulin and Risk of Hyperglycemia in Patients With Androgenetic Alopecia

36 citations , July 2011 in “Journal of The American Academy of Dermatology”

People with hair loss have higher risk of high blood sugar and diabetes, and lower levels of a specific hormone.

research Lipid Levels in Women with Androgenetic Alopecia

15 citations , November 2010 in “International Journal of Dermatology”

Women with AGA have higher lipid levels, increasing heart disease risk.

research Androgenetic Alopecia and Cardiovascular Risk Factors in Men and Women: A Comparative Study

110 citations , July 2010 in “Journal of The American Academy of Dermatology”

Hair loss linked to higher heart disease risk in both men and women.

research Male Androgenetic Alopecia and Cardiovascular Risk Factors: A Case-Control Study

23 citations , April 2010 in “Actas Dermo-Sifiliográficas”

Men with early-onset baldness have a higher chance of heart disease and clogged arteries.

research A Comparative Study of Dyslipidemia in Men and Women with Androgenic Alopecia

37 citations , January 2010 in “Acta dermato-venereologica”

People with early onset baldness have higher bad cholesterol and lower good cholesterol, increasing their heart disease risk.

research Hypertension and Aldosterone Levels in Women with Early-Onset Androgenetic Alopecia

45 citations , November 2009 in “British Journal of Dermatology”

Women with early hair loss have higher blood pressure and aldosterone; screening and treatment may help.

research Elevated Aldosterone Levels in Patients with Androgenetic Alopecia

30 citations , November 2009 in “British Journal of Dermatology”

Higher aldosterone levels link to hair loss and high blood pressure.

research Does Degree of Baldness Influence Vitamin D Status?

19 citations , December 2008 in “Medical Journal of Australia”

Baldness does not affect vitamin D levels in men.

research Baldness, Benign Prostate Hyperplasia, Prostate Cancer, and Androgen Levels

30 citations , January 2008 in “The Aging Male”

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

215 citations , November 2006 in “Journal of The American Academy of Dermatology”

Dutasteride more effective for hair growth, but has more side effects than finasteride.

research Protection Against Chemotherapy-Induced Alopecia

97 citations , September 2006 in “Pharmaceutical Research”

No treatment fully prevents hair loss from chemotherapy yet.

research The Preventive Effect of Vitamin D3 on Radiation-Induced Hair Toxicity in a Rat Model

14 citations , November 2005 in “Life sciences”

Vitamin D3 may protect rat hair follicles from radiation damage.

research Patients With a Large Prostate Show a Higher Prevalence of Androgenetic Alopecia

4 citations , November 2005 in “The Journal of Urology”

Large prostates link to more hair loss.

research Patients With a Large Prostate Show a Higher Prevalence of Androgenetic Alopecia

33 citations , October 2004 in “Archives of Dermatological Research”

Large prostate links to more hair loss, but age of onset doesn't affect it.

research Androgenetic Alopecia in Men Aged 40-69 Years: Prevalence and Risk Factors

155 citations , December 2003 in “British Journal of Dermatology”

Hair loss increases with age; alcohol raises risk, more female partners lowers it.

research Hormonal Treatment for Male-Pattern Hair Loss: Implications for Cancer of the Prostate

4 citations , October 2002 in “BJUI”

Finasteride treats hair loss but may affect prostate cancer detection.

research Association of Benign Prostatic Hyperplasia with Male Pattern Baldness

54 citations , May 1998 in “Urology”

Men with enlarged prostates often have more severe baldness.

research The Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Scalp Skin Testosterone and Dihydrotestosterone Concentrations in Patients With Male Pattern Baldness

61 citations , September 1994 in “The Journal of Clinical Endocrinology and Metabolism”

research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1040 citations , October 1992 in “The New England Journal of Medicine”

Finasteride effectively treats BPH but may increase sexual dysfunction risk.

Related Community Posts Join

6 / 1000+ results

community Massive study on finasteride side effects released

in Finasteride/Dutasteride 83 upvotes 2 years ago

The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

community Dutasteride Infertility Debunked: Low T causes true infertility.

in Finasteride/Dutasteride 168 upvotes 6 months ago

Dutasteride and finasteride may temporarily affect semen quality but are unlikely to cause permanent infertility. The Kim et al. study is criticized for poor methodology, and many prefer hair retention over potential fertility concerns, using treatments like dutasteride, finasteride, and minoxidil.

community Taking Charge of Your Hair: The "Big 3 Stack" Explained for 2023

in Research/Science 131 upvotes 2 years ago

The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.

community Sexual Dysfunction in Those with Androgenetic Alopecia on Dutasteride Versus Finasteride

in Finasteride/Dutasteride 113 upvotes 4 months ago

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

community 31M. Just diagnosed with androgenic alopecia. Fears of min.

in Finasteride/Dutasteride 12 upvotes 1 month ago

A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 1 year ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.